CEB 1050

Drug Profile

CEB 1050

Latest Information Update: 15 Aug 2000

Price : $50

At a glance

  • Originator Vernalis Group
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Behavioural disorders

Most Recent Events

  • 15 Aug 2000 Discontinued-II for Behavioural disorders in USA (Unknown route)
  • 24 May 2000 Vanguard Medica is now called Vernalis Group
  • 29 Feb 2000 Cerebrus Pharmaceuticals has been acquired by Vanguard Medica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top